DiaSorin (DIA) Stock Overview
Engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
DIA Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
DiaSorin S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €58.92 |
| 52 Week High | €108.00 |
| 52 Week Low | €58.84 |
| Beta | 0.53 |
| 1 Month Change | -21.38% |
| 3 Month Change | -29.89% |
| 1 Year Change | -44.99% |
| 3 Year Change | -55.40% |
| 5 Year Change | -66.08% |
| Change since IPO | 375.93% |
Recent News & Updates
These 4 Measures Indicate That DiaSorin (BIT:DIA) Is Using Debt Reasonably Well
Oct 02
Getting In Cheap On DiaSorin S.p.A. (BIT:DIA) Is Unlikely
Aug 18DiaSorin S.p.A. (BIT:DIA) Just Released Its Interim Earnings: Here's What Analysts Think
Aug 03Recent updates
These 4 Measures Indicate That DiaSorin (BIT:DIA) Is Using Debt Reasonably Well
Oct 02Getting In Cheap On DiaSorin S.p.A. (BIT:DIA) Is Unlikely
Aug 18DiaSorin S.p.A. (BIT:DIA) Just Released Its Interim Earnings: Here's What Analysts Think
Aug 03A Look At The Intrinsic Value Of DiaSorin S.p.A. (BIT:DIA)
Jul 29DiaSorin (BIT:DIA) Has A Rock Solid Balance Sheet
Jun 20DiaSorin's (BIT:DIA) Upcoming Dividend Will Be Larger Than Last Year's
Mar 20Is DiaSorin (BIT:DIA) Using Too Much Debt?
Mar 16
MeMed, LIAISON PLEX, And Global Expansion Set To Boost Revenue And Earnings Growth
Strong hospital strategy and new product offerings in the U.S. could drive significant revenue growth and new hospital additions.Is DiaSorin (BIT:DIA) A Risky Investment?
Nov 29DiaSorin S.p.A. (BIT:DIA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 08DiaSorin S.p.A. (BIT:DIA) Investors Are Less Pessimistic Than Expected
Aug 23DiaSorin S.p.A. (BIT:DIA) Just Released Its Interim Results And Analysts Are Updating Their Estimates
Aug 01We Think DiaSorin (BIT:DIA) Can Stay On Top Of Its Debt
Jul 16DiaSorin's (BIT:DIA) Dividend Will Be Increased To €1.15
Apr 09DiaSorin (BIT:DIA) Is Paying Out A Larger Dividend Than Last Year
Mar 25DiaSorin S.p.A. (BIT:DIA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Mar 20DiaSorin S.p.A.'s (BIT:DIA) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 17Is DiaSorin (BIT:DIA) Using Too Much Debt?
Jan 25Some May Be Optimistic About DiaSorin's (BIT:DIA) Earnings
Nov 11DiaSorin S.p.A.'s (BIT:DIA) Intrinsic Value Is Potentially 24% Below Its Share Price
Oct 11Is DiaSorin (BIT:DIA) A Risky Investment?
Sep 19Does DiaSorin (BIT:DIA) Have A Healthy Balance Sheet?
May 01DiaSorin (BIT:DIA) Is Increasing Its Dividend To €1.10
Apr 02Does DiaSorin (BIT:DIA) Have A Healthy Balance Sheet?
Jan 07These 4 Measures Indicate That DiaSorin (BIT:DIA) Is Using Debt Reasonably Well
Sep 13Are DiaSorin S.p.A. (BIT:DIA) Investors Paying Above The Intrinsic Value?
Aug 17DiaSorin (BIT:DIA) Has A Pretty Healthy Balance Sheet
Jun 14DiaSorin (BIT:DIA) Will Pay A Larger Dividend Than Last Year At €1.05
May 19DiaSorin's (BIT:DIA) Shareholders Will Receive A Bigger Dividend Than Last Year
May 03Calculating The Fair Value Of DiaSorin S.p.A. (BIT:DIA)
May 01DiaSorin (BIT:DIA) Is Paying Out A Larger Dividend Than Last Year
Apr 13DiaSorin (BIT:DIA) Is Increasing Its Dividend To €1.05
Mar 21Here's Why I Think DiaSorin (BIT:DIA) Is An Interesting Stock
Mar 02Is DiaSorin S.p.A. (BIT:DIA) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 19Is DiaSorin (BIT:DIA) Using Too Much Debt?
Dec 04Does DiaSorin (BIT:DIA) Deserve A Spot On Your Watchlist?
Oct 18Is DiaSorin (BIT:DIA) A Risky Investment?
Aug 23Industry Analysts Just Upgraded Their DiaSorin S.p.A. (BIT:DIA) Revenue Forecasts By 12%
Jul 15Here's Why I Think DiaSorin (BIT:DIA) Might Deserve Your Attention Today
Jul 13Does DiaSorin (BIT:DIA) Deserve A Spot On Your Watchlist?
Apr 02DiaSorin S.p.A.'s (BIT:DIA) 0.7% Dividend Yield Looks Pretty Interesting
Mar 15Are Institutions Heavily Invested In DiaSorin S.p.A.'s (BIT:DIA) Shares?
Feb 25Returns On Capital - An Important Metric For DiaSorin (BIT:DIA)
Feb 04
Did You Participate In Any Of DiaSorin's (BIT:DIA) Incredible 311% Return?
Jan 14Is Now The Time To Put DiaSorin (BIT:DIA) On Your Watchlist?
Dec 24Are Robust Financials Driving The Recent Rally In DiaSorin S.p.A.'s (BIT:DIA) Stock?
Dec 02Shareholder Returns
| DIA | IT Medical Equipment | IT Market | |
|---|---|---|---|
| 7D | -0.5% | 0.1% | 2.3% |
| 1Y | -45.0% | -37.0% | 27.2% |
Return vs Industry: DIA underperformed the Italian Medical Equipment industry which returned -37% over the past year.
Return vs Market: DIA underperformed the Italian Market which returned 27.2% over the past year.
Price Volatility
| DIA volatility | |
|---|---|
| DIA Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in IT Market | 7.6% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: DIA's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: DIA's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 3,280 | Carlo Rosa | int.diasorin.com |
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens.
DiaSorin S.p.A. Fundamentals Summary
| DIA fundamental statistics | |
|---|---|
| Market cap | €3.18b |
| Earnings (TTM) | €184.11m |
| Revenue (TTM) | €1.21b |
Is DIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIA income statement (TTM) | |
|---|---|
| Revenue | €1.21b |
| Cost of Revenue | €417.21m |
| Gross Profit | €792.22m |
| Other Expenses | €608.11m |
| Earnings | €184.11m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.41 |
| Gross Margin | 65.50% |
| Net Profit Margin | 15.22% |
| Debt/Equity Ratio | 39.3% |
How did DIA perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/15 06:07 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DiaSorin S.p.A. is covered by 33 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paola Saglietti | Banca Akros S.p.A. (ESN) |
| Gaurav Jain | Barclays |
| Charles Pitman | Barclays |